Provectus Biopharmaceuticals Announces Notice of Allowance for US Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)

Provectus Biopharmaceuticals, Inc.announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers”.